✦ LIBER ✦

Analysis of cytotoxic T lymphocytes and Fas/FasL in Japanese patients with non-small cell lung cancer associated with HLA-A2

✍ Scribed by Chie Yoshimura; Shosaku Nomura; Shigenori Kanazawa; Midori Kuwana; Mikiko Muramatsu; Kazuyuki Yamaguchi; Shirou Fukuhara

Publisher: Springer-Verlag
Year: 2002
Tongue: English
Weight: 318 KB
Volume: 128
Category: Article
ISSN: 1432-1335
DOI: 10.1007/s00432-002-0381-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

CD80 expression in an HLA-A2-positive hu

CD80 expression in an HLA-A2-positive human non-small cell lung cancer cell line enhances tumor-specific cytotoxicity of HLA-A2-positive T cells derived from a normal donor and a patient with non-small cell lung cancer

✍ Dale L. Bixby; John R. Yannelli 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 185 KB 👁 2 views

To generate non-small cell lung cancer (NSCLC)-reactive lymphocytes, we transfected an HLA-A2-expressing human NSCLC line (1355) with the cDNA encoding the lymphocyte co-stimulatory molecule CD80. Following selection in G418, 1355.7 demonstrated stable cell-surface expression of CD80. Allogeneic mix

Analysis of related factors associated w

✍ Jun Dang; Guang Li; Xiaobe Lu; Lei Yao; Shuo Zhang; Zhan Yu 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 362 KB

Associations of ABCB1, ABCC2, and ABCG2

Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer

✍ Ji-Youn Han; Hyeong-Seok Lim; Yeon-Kyeong Yoo; Eun Soon Shin; Yong Hoon Park; Su 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 215 KB 👁 2 views

## Abstract ## BACKGROUND. The authors investigated whether __ABCB1, ABCC2,__ and __ABCG2__ genetic polymorphisms affect pharmacokinetics (PK) of irinotecan and treatment outcome of patients with advanced nonsmall cell lung cancer (NSCLC). ## METHODS. Blood samples from 107 NSCLC patients treate

Phase I trial of non-cytotoxic suramin a

Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer

✍ Elaine T. Lam; Jessie L.- S. Au; Gregory A. Otterson; M. Guillaume Wientjes; Lin 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 422 KB

Docetaxel as salvage chemotherapy in pat

Docetaxel as salvage chemotherapy in patients with advanced non-small cell lung cancer after failure of cytotoxic agents and gefitinib treatment

✍ Yilong Wu; Jinji Yang; Yujuan Huang; Qin Zhou; Yisheng Huang; Chongrui Xu 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 545 KB

Erratum: Associations of ABCB1, ABCC2, a

Erratum: Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer

✍ Ji-Youn Han; Hyeong-Seok Lim; Yeon-Kyeong Yoo; Eun Soon Shin; Yong Hoon Park; Su 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB 👁 1 views